Business
Statement re Annual Report and Notice of AGM
Statement re Annual Report and Notice of AGM.
About this update from Ixico Plc
[{"type":"text","content":"\n \nRNS Number : 5652X IXICO plc 20 December 2019 \n\n20 December 2019\nIXICO plc\n(\"IXICO\" or the \"Company\")\n \nPosting of Annual Report and Notice of AGM\nIXICO plc (AIM: IXI), the AI data analytics company delivering insights in neuroscience, confirms that the Annual Report and Accounts for the year ended 30 September 2019 (\"Annual Report and Accounts 2019\") and the Notice of Annual General Meeting (\"AGM\") have been posted to shareholders on 12 December and 16 December, respectively. A copy of the 2019 Annual Report and Accounts is available to download from the Company website on www.IXICO.com.\n \nThe AGM will be held at BGF Investment Management, 13-15 York Buildings, London, WC2N 6JU on 17 January 2020 at 10.30 a.m.\n \nFor further information please contact: \n \n\n\n\nIXICO plc\n\n\n+44 (0) 20 3763 7498\n\n\n\n\nGiulio Cerroni, Chief Executive Officer\nGrant Nash, Chief Financial Officer\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nCenkos Securities PLC (Nominated adviser and sole broker)\n\n\n+44 (0) 20 7397 8900\n\n\n\n\nGiles Balleny / Max Gould (Corporate Finance)\n\n\n\n\n\n\n\nMichael F Johnson / Russell Kerr (Sales)\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nOptimum Strategic Communications\n\n\n +44 (0) 203 950 9144\n\n\n\n\nMary Clark / Supriya Mathur / Manel Mateus\n\n\n\n\n\n\n\[email protected]\n\n\n\n\n\n\n \nAbout IXICO\nIXICO's purpose is to advance medicine and human health by turning data into clinically meaningful information, providing valuable new insights in neuroscience and rare disease.\nOur goal is to be a leading proponent in the use of Artificial Intelligence (AI) in clinical development, to improve biopharma R&D productivity through the adoption of breakthrough data analytics in precision healthcare. Through the deployment of novel AI algorithms, we analyse and interpret brain scans and digital biosensor data to enable better trial design, patient selection and ultimately clinical outcomes across all phases of clinical evaluation. Our data analytics services are deployed on some of the most important clinical trials in neuroscience, providing valuable insights to disease progression and patient safety, enabling our clients to make better informed decisions earlier in the clinical development pathway.\n \n More information is available on www.IXICO.com\n&...